Aspect Biosystems to Present at 2024 Cell & Gene Meeting on the Med

Apr 04, 2024

Vancouver, BC, Canada – April 4, 2024 – Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, announced today that CEO Tamer Mohamed will present at the annual Cell & Gene Meeting on the Med to be held April 9-11, 2024 in Rome, Italy and livestreamed globally.

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Med is a three-day conference featuring more than 60 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.

The following are specific details regarding Aspect Biosystems’ presentation at the conference:

2024 Cell & Gene Meeting on the Med 
DateTuesday, April 9, 2024 
9:45am CEST
LocationRome Cavalieri, A Waldorf Astoria Hotel
Via Alberto Cadlolo, 101, 00136 Roma RM, Italy

Virtual attendance is available which includes a livestream of Aspect Biosystems’ presentation and the ability to view all conference sessions on-demand. Please visit for full information including registration. 

About Aspect Biosystems

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of currently incurable diseases. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body. The company’s current therapeutic pipeline is focused on metabolic and endocrine diseases such as diabetes, obesity, and congenital liver disorders. Learn more at


Natalie Korenic
Aspect Biosystems

Back to all